MDXG News and Press, MiMedx Group Inc From 10/16/23

MARIETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2023 after the market close on Monday, Octob...

2023-10-04 05:43:37 ET Summary MiMedx had strong Q2 2023 performance, particularly in Wound & Surgical; operational efficiency achieved but concerns over disbanding Regenerative Health division. Balance sheet healthy; liquidity robust but market signals caution with equity dil...

MARIETTA, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIEFFECT™, the Company’s latest addition to its portfolio of AWC solutions. EPIEFFECT expands the Company&...

YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a research collaboration agreement with MIMEDX Group, Inc (Nasdaq: ...

2023-08-01 18:48:03 ET MiMedx Group, Inc. (MDXG) Q2 2023 Earnings Conference Call August 01, 2023 05:00 PM ET Company Participants Matt Notarianni - Head, Investor Relations Joe Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference...

2023-08-01 16:19:28 ET MiMedx Group press release ( NASDAQ: MDXG ): Q2 GAAP EPS of $0.00 beats by $0.03 . Revenue of $81.3M (+21.6% Y/Y) beats by $6.47M . As a result of our progress to date, we are increasing guidance for our full-year 2023 net sales percentag...

Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive as Chief Financial Officer Management to Host Conference Call on Tuesday...

2023-07-31 17:35:53 ET MiMedx Group ( NASDAQ: MDXG ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, after market close. The consensus EPS Estimate is -$0.03 and the consensus Revenue Estimate is $74.83M (+11.9% Y/Y). For further details see: ...

2023-07-25 08:11:12 ET Summary MiMedx has announced its intention to exit the knee osteoarthritis business to instead focus efforts on the high-growth Wound biologics market. The restructuring is expected to improve cash flow and profitability, supporting a positive long-term outl...

MARIETTA, Ga., July 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 1...